antiviral news

Press Releases in the global landscape

Mar 12, 2026

Preclinical data for MDL-001 indicates potential across multiple viral infections

Preclinical data suggests that MDL-001, an oral antiviral candidate, may have activity across multiple viral families, supporting its development as a potential broad-spectrum antiviral therapy.

Mar 11, 2026

CDC: Antiviral use low among older COVID outpatients, despite higher risk for severe disease

Only 16% to 38% of non-hospitalized US COVID-19 patients aged 65 years and older were given an antiviral prescription.

Mar 9, 2026

GlobalData report highlights Model Medicines antiviral MDL-001

A GlobalData report highlighted Model Medicines’ experimental antiviral candidate MDL-001, noting its potential role in future pandemic preparedness efforts. The analysis points to the drug’s possible value in responding to emerging infectious disease threats.

Mar 4, 2026

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients.

Mar 2, 2026

Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M

Bioxytran reported positive Phase 1b/2a trial results for its antiviral candidate ProLectin-M in mild to moderate COVID-19, showing faster viral clearance and a favorable safety profile.

Feb 27, 2026

KDCA to halt use of unapproved Covid-19 drug Lagevrio as stock runs out

The Korea Disease Control and Prevention Agency announced it will suspend use of the COVID-19 drug Lagevrio (molnupiravir) due to depleted stock and incomplete product approval.